Astellas CEO Yasukawa On Gene Therapy Challenges, Deal Strategies
Keen Focus On Tech
Executive Summary
Despite facing two clinical holds for its gene therapy candidates, Astellas is committed to proceeding with R&D projects in this modality. Outgoing CEO Kenji Yasukawa says technical challenges have motivated the firm's recent deals with academia and bioventures, and also provided updates on other key pipeline assets in the second part of this exclusive interview with Scrip.
You may also be interested in...
Asia Deal Watch: Avenue Takes On AnnJi’s Spinal And Bulbar Muscular Atrophy Candidate
Plus deals involving Ono/PeptiDream, Onconic/Livzon, Teijin/Novartis, Eisai/Biogen, Abbisko/Allist, Daewoong/M8, GC Biopharma/Catalyst and KYM Biosciences/AstraZeneca.
Astellas CEO Yasukawa On Enabling Faster R&D
Keeping the company focus on launching innovating drugs, Astellas CEO Kenji Yasukawa talks in part one of this exclusive interview on how the Japanese firm transformed its R&D processes to allow more flexible and agile decision-making beyond the wall of multiple sections.
2023 Will Be A Year Of Partnerships And Acquisitions For Astellas
Astellas’ Mike Luther sees 2023 as a year of growing assets and creating partnerships. The global head of search and evaluation business development told In Vivo about the company's focus on gene and cell therapy and what he thinks makes for a successful business deal.